EA202090184A2 - Пептидные композиции и способы использования - Google Patents

Пептидные композиции и способы использования

Info

Publication number
EA202090184A2
EA202090184A2 EA202090184A EA202090184A EA202090184A2 EA 202090184 A2 EA202090184 A2 EA 202090184A2 EA 202090184 A EA202090184 A EA 202090184A EA 202090184 A EA202090184 A EA 202090184A EA 202090184 A2 EA202090184 A2 EA 202090184A2
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
peptide compositions
photoreceptor
fas
trail
Prior art date
Application number
EA202090184A
Other languages
English (en)
Other versions
EA202090184A3 (ru
Inventor
Кагри Г. Бесирли
Александер Дж. Бриджес
Джон К. Фрешли
Вильям А. Ханке
Линда Л. Джонсон
Френсис Х. Смит
Итан Сильвен
Дэвид Н. Закс
Original Assignee
ОЭнЭл ТЕРАПЬЮТИКС, ИНК.
Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ОЭнЭл ТЕРАПЬЮТИКС, ИНК., Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган filed Critical ОЭнЭл ТЕРАПЬЮТИКС, ИНК.
Publication of EA202090184A2 publication Critical patent/EA202090184A2/ru
Publication of EA202090184A3 publication Critical patent/EA202090184A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Pest Control & Pesticides (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Agronomy & Crop Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

В изобретении представлены композиции, включающие пептиды, их фармацевтические препараты и способы предотвращения с их помощью смерти фоторецепторов и защиты клеток сетчатки, включая, но без ограничения, фоторецепторные и пигментный эпителии сетчатки, от Fas- или TRAIL-опосредованного апоптоза.
EA202090184A 2015-05-01 2016-04-29 Пептидные композиции и способы использования EA202090184A3 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562155711P 2015-05-01 2015-05-01

Publications (2)

Publication Number Publication Date
EA202090184A2 true EA202090184A2 (ru) 2020-05-31
EA202090184A3 EA202090184A3 (ru) 2020-07-31

Family

ID=57217771

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201792399A EA035293B1 (ru) 2015-05-01 2016-04-29 Пептидные композиции и способы использования
EA202090184A EA202090184A3 (ru) 2015-05-01 2016-04-29 Пептидные композиции и способы использования

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201792399A EA035293B1 (ru) 2015-05-01 2016-04-29 Пептидные композиции и способы использования

Country Status (22)

Country Link
US (4) US10508134B2 (ru)
EP (2) EP3997981A1 (ru)
JP (2) JP6884755B2 (ru)
KR (2) KR102652804B1 (ru)
CN (2) CN113651873A (ru)
AU (1) AU2016258837B2 (ru)
BR (1) BR112017023479A2 (ru)
CA (1) CA2984154A1 (ru)
CY (1) CY1124911T1 (ru)
DK (1) DK3288379T3 (ru)
EA (2) EA035293B1 (ru)
ES (1) ES2906173T3 (ru)
HK (1) HK1251979A1 (ru)
HR (1) HRP20220138T1 (ru)
HU (1) HUE057883T2 (ru)
LT (1) LT3288379T (ru)
MX (1) MX2017014075A (ru)
PL (1) PL3288379T3 (ru)
PT (1) PT3288379T (ru)
RS (1) RS62866B1 (ru)
SI (1) SI3288379T1 (ru)
WO (1) WO2016178993A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62866B1 (sr) * 2015-05-01 2022-02-28 Onl Therapeutics Inc Kompozicije peptida i postupci upotrebe
WO2019183246A1 (en) * 2018-03-20 2019-09-26 Onl Therapeutics, Inc. Compositions and methods of fas inhibition
JP2021531327A (ja) * 2018-06-19 2021-11-18 セラ セラピューティクス エルエルシー 眼圧降下剤、ｃｎｐ化合物、ｎｒｐ−ｂ化合物、ｔｉｅ−２アゴニスト、または神経栄養剤を含む、緑内障または高眼圧症を治療するための徐放性薬剤送達系
US20230094423A1 (en) * 2019-12-18 2023-03-30 Cella Therapeutics, Llc Drug delivery systems comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (fas) or fas ligand (fasl) inhibitor, a tumor necrosis factor-alpha (tnf-alpha) or tnf receptor inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-aspartic protease inhibitor
WO2023129766A1 (en) * 2021-12-27 2023-07-06 Onl Therapeutics, Inc. Sfasl for inhibiting rpe cell death and associated disorders
WO2024031024A1 (en) * 2022-08-05 2024-02-08 Onl Therapeutics, Inc. Peptide compositions and methods of use
WO2024031022A2 (en) * 2022-08-05 2024-02-08 Onl Therapeutics, Inc. Peptide compositions and methods of use

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5532123A (en) * 1990-07-11 1996-07-02 New York University Receptor-type phosphotyrosine phosphatase-γ
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
JP3187201B2 (ja) * 1992-05-14 2001-07-11 三共株式会社 Ｃ末端にプロリンアミドを有するペプチドの製法
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
JP3460863B2 (ja) 1993-09-17 2003-10-27 三菱電機株式会社 半導体装置の製造方法
US5714353A (en) 1994-05-24 1998-02-03 Research Corporation Technologies, Inc. Safe vectors for gene therapy
US5527928A (en) 1994-09-30 1996-06-18 Nantz; Michael H. Cationic transport reagents
US5719131A (en) 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
US5650096A (en) 1994-12-09 1997-07-22 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5705385A (en) 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5711964A (en) 1995-06-07 1998-01-27 United States Of America Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D
US6001962A (en) * 1996-11-15 1999-12-14 The Regents Of The University Of California Modified Fas ligands
US7091047B2 (en) * 1997-05-23 2006-08-15 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity
US6363020B1 (en) 1999-12-06 2002-03-26 Virage Logic Corp. Architecture with multi-instance redundancy implementation
US6480428B2 (en) 2000-12-19 2002-11-12 Winbond Electronics Corporation Redundant circuit for memory device
JP2008500816A (ja) * 2004-03-31 2008-01-17 ゼンコー・インコーポレイテッド 改善された性質を有するｂｍｐ−７変異体
CA2563691A1 (en) 2004-04-23 2005-12-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Cell death modulation via antagonists of fasl and fas activation
DK1885336T3 (da) * 2005-05-10 2009-05-25 Alcon Inc Suspensionsformuleringer, der omfatter et aktivt princip, et overfladeaktivt poloxamer- eller meroxapolmiddel og en glycol, samt deres anvendelse til fremstilling af et medikament til behandling af öjenlidelser
CN101355876B (zh) * 2005-11-09 2012-09-05 康宾纳特克斯公司 一种适用于眼部给药的组合物
JP2009518308A (ja) * 2005-12-01 2009-05-07 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション アポトーシスを阻害するための化合物及び方法
US20110039773A1 (en) * 2007-12-21 2011-02-17 Stryker Biotech BMP Mutants with Decreased Susceptibility to Noggin
US8343931B2 (en) 2009-03-03 2013-01-01 The Regents Of The University Of Michigan Methods of inhibiting photoreceptor apoptosis
EA201171188A1 (ru) * 2009-03-30 2012-05-30 Сантен Фармасьютикал Ко., Лтд. Профилактическое или терапевтическое средство против болезни сетчатки и способ профилактики или лечения болезни сетчатки с использованием jnk (c-jun-аминоконцевая киназа)-ингибиторного пептида, а также применение указанного пептида
JP2013501064A (ja) * 2009-08-04 2013-01-10 アミラ ファーマシューティカルス，インコーポレーテッド リゾホスファチジン酸受容体アンタゴニストとしての化合物
WO2012115980A1 (en) 2011-02-22 2012-08-30 California Institute Of Technology Delivery of proteins using adeno-associated virus (aav) vectors
JP6250536B2 (ja) * 2011-06-06 2017-12-20 ケイ・ブイ・１．３・セラピューティクス・インコーポレイテッド Ｓｈｋベースの薬学的組成物とその製造方法および使用方法
US9428550B2 (en) 2012-01-18 2016-08-30 Governing Council Of The University Of Toronto Peptides and methods and uses thereof for preventing retinal disorders
CN104394881B (zh) * 2012-06-21 2016-10-26 韩诺生物制药株式会社 修饰的人肿瘤坏死因子受体-1多肽的新用途
EP2916859B1 (en) * 2012-11-02 2017-06-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor
US20180024145A1 (en) 2015-02-05 2018-01-25 Immunarray USA, Inc. Methods and compositions for diagnosing brain injury or neurodegeneration
RS62866B1 (sr) * 2015-05-01 2022-02-28 Onl Therapeutics Inc Kompozicije peptida i postupci upotrebe
US20190201500A1 (en) 2015-05-01 2019-07-04 Onl Therapeutics, Inc. Compositions and methods of fas inhibition
WO2018009553A1 (en) 2016-07-05 2018-01-11 University Of Massachusetts Aav2-mediated gene delivery of sfasl as a neuroprotective therapy in glaucoma
WO2019183246A1 (en) 2018-03-20 2019-09-26 Onl Therapeutics, Inc. Compositions and methods of fas inhibition
JP2021531327A (ja) 2018-06-19 2021-11-18 セラ セラピューティクス エルエルシー 眼圧降下剤、ｃｎｐ化合物、ｎｒｐ−ｂ化合物、ｔｉｅ−２アゴニスト、または神経栄養剤を含む、緑内障または高眼圧症を治療するための徐放性薬剤送達系

Also Published As

Publication number Publication date
EA035293B1 (ru) 2020-05-26
AU2016258837A1 (en) 2017-11-09
US20210094985A1 (en) 2021-04-01
DK3288379T3 (da) 2022-02-07
JP6884755B2 (ja) 2021-06-09
EP3288379B1 (en) 2021-11-03
PT3288379T (pt) 2022-02-08
KR20170140383A (ko) 2017-12-20
US20180291062A1 (en) 2018-10-11
BR112017023479A2 (pt) 2018-07-24
AU2016258837B2 (en) 2020-12-03
HK1251979A1 (zh) 2019-05-10
EA201792399A1 (ru) 2018-05-31
CN107708416B (zh) 2021-06-29
EA202090184A3 (ru) 2020-07-31
EP3288379A1 (en) 2018-03-07
US10508134B2 (en) 2019-12-17
PL3288379T3 (pl) 2022-03-07
US10829518B2 (en) 2020-11-10
LT3288379T (lt) 2022-02-25
US20230287052A1 (en) 2023-09-14
KR20240046280A (ko) 2024-04-08
SI3288379T1 (sl) 2022-06-30
ES2906173T3 (es) 2022-04-13
CN113651873A (zh) 2021-11-16
CY1124911T1 (el) 2023-01-05
US11597749B2 (en) 2023-03-07
JP2021120400A (ja) 2021-08-19
EP3997981A1 (en) 2022-05-18
JP2018514590A (ja) 2018-06-07
EP3288379A4 (en) 2018-10-24
HRP20220138T1 (hr) 2022-05-27
HUE057883T2 (hu) 2022-06-28
US20200123201A1 (en) 2020-04-23
RS62866B1 (sr) 2022-02-28
CN107708416A (zh) 2018-02-16
KR102652804B1 (ko) 2024-04-01
CA2984154A1 (en) 2016-11-10
WO2016178993A1 (en) 2016-11-10
MX2017014075A (es) 2018-07-06

Similar Documents

Publication Publication Date Title
EA202090184A2 (ru) Пептидные композиции и способы использования
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
CL2018001587A1 (es) Anticuerpos neutralizadores del virus de inmunodeficiencia humana
BR112017025892A2 (pt) vetores de vírus adeno-associados para o tratamento de mucolopissacaridoses
EA201891087A1 (ru) Ингибиторы ret
BR112016025819A2 (pt) vetores de vírus adeno-associados para o tratamento de doenças de depósito lisossômico
EA201591599A1 (ru) Ингибиторы ido
EA201690306A1 (ru) Ингибиторы ido
EA201690152A1 (ru) Ингибиторы ido
EA201591823A1 (ru) Ингибиторы ido
EA201691582A1 (ru) Новые фармацевтические препараты
EA201690027A1 (ru) Ингибиторы ido
EA201790922A1 (ru) Ингибиторы бромодомена
EA201591661A1 (ru) Пептиды и композиции для лечения повреждений суставов
EA201690159A1 (ru) Способы и композиции для лечения рака
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
EA201792262A1 (ru) Пироглутамат вортиоксетина
EA201791249A1 (ru) Получаемые из cd44v6 циклические пептиды для лечения злокачественных опухолей и связанных с ангиогенезом заболеваний
EA202091567A1 (ru) Химерные белки мти
EA201790893A1 (ru) Способы лечения офтальмологических расстройств
EA201691792A1 (ru) Фармацевтические составы на основе вилдаглиптина
EA202190057A1 (ru) Солюбилизированные апиразы, способы и применение
MX2016000448A (es) Péptidos y análogos peptídicos protectores de tejido para prevenir y tratar enfermedades y trastornos asociados con daño del tejido.
DK3509573T3 (da) Farmaceutiske sammensætninger til indgivelse af peptid
EA202191758A1 (ru) Пептиды для лечения и профилактики диабета и связанных с ним заболеваний